A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib.
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2015
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CMR-CML
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
- 14 Jun 2015 Status changed from active, no longer recruiting to completed, according to abstract presented at 20th Congress of the European Haematology Association, which stated that patients were enrolled between 6 aug 2011 and 17 Jan 2013.
- 29 Apr 2011 New trial record